Ohsu Knight Cancer Institute
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Employees
- -
- Market Cap
- -
MRI Assessment of Leukemia Response to Therapy
- Conditions
- Interventions
- First Posted Date
- 2012-02-23
- Last Posted Date
- 2019-07-30
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 23
- Registration Number
- NCT01537159
- Locations
- 🇺🇸
Oregon Health and Science University, Portland, Oregon, United States
Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2012-02-14
- Last Posted Date
- 2021-09-27
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 54
- Registration Number
- NCT01532687
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸OHSU Knight Cancer Institute, Portland, Oregon, United States
Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
- First Posted Date
- 2011-12-26
- Last Posted Date
- 2020-10-14
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 10
- Registration Number
- NCT01498978
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸OHSU Knight Cancer Institute, Portland, Oregon, United States
Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN)
- Conditions
- Interventions
- First Posted Date
- 2011-11-06
- Last Posted Date
- 2014-11-19
- Lead Sponsor
- OHSU Knight Cancer Institute
- Registration Number
- NCT01465815
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Dasatinib in Treating Patients With Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2011-09-28
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 19
- Registration Number
- NCT01441882
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Fluocinonide Cream in Treating Symptoms of Vaginal Dryness and Painful Sexual Intercourse In Patients With Breast Cancer Undergoing Hormone Therapy
- Conditions
- Interventions
- First Posted Date
- 2011-08-24
- Last Posted Date
- 2017-08-09
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 34
- Registration Number
- NCT01422408
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma
- First Posted Date
- 2011-07-19
- Last Posted Date
- 2014-07-30
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 3
- Registration Number
- NCT01397591
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Comparing Warm Versus Cool Temperature Water During Colonoscopy
- First Posted Date
- 2011-03-25
- Last Posted Date
- 2012-05-25
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 175
- Registration Number
- NCT01322724
- Locations
- 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States
Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel
- First Posted Date
- 2010-12-03
- Last Posted Date
- 2019-10-02
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 11
- Registration Number
- NCT01253642
- Locations
- 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸OHSU Knight Cancer Institute, Portland, Oregon, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Sulforaphane in Treating Patients With Recurrent Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-10-25
- Last Posted Date
- 2017-04-28
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 20
- Registration Number
- NCT01228084
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States